Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of “Hold” by Brokerages

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have been assigned an average rating of “Hold” from the fourteen brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $15.55.

A number of research firms have issued reports on FOLD. The Goldman Sachs Group lifted their target price on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Monday, December 29th. Jefferies Financial Group restated a “hold” rating and issued a $14.50 price objective (down previously from $16.00) on shares of Amicus Therapeutics in a research note on Thursday, January 22nd. Zacks Research cut shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 26th. Finally, Needham & Company LLC cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 19th.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $14.29 on Friday. The company’s 50 day moving average price is $12.70 and its 200 day moving average price is $9.58. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.09 and a current ratio of 2.99. Amicus Therapeutics has a 52 week low of $5.51 and a 52 week high of $14.38. The company has a market capitalization of $4.48 billion, a PE ratio of -357.16 and a beta of 0.42.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The business had revenue of $169.06 million for the quarter, compared to the consensus estimate of $165.24 million. During the same period in the prior year, the business posted $0.10 earnings per share. Amicus Therapeutics’s revenue for the quarter was up 19.5% compared to the same quarter last year. Research analysts expect that Amicus Therapeutics will post 0.15 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Jeff Castelli sold 76,158 shares of Amicus Therapeutics stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $10.16, for a total transaction of $773,765.28. Following the completion of the transaction, the insider directly owned 439,318 shares of the company’s stock, valued at $4,463,470.88. This trade represents a 14.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Michael Clark sold 25,643 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $9.51, for a total transaction of $243,864.93. Following the completion of the transaction, the insider owned 322,618 shares of the company’s stock, valued at $3,068,097.18. This trade represents a 7.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 420,450 shares of company stock worth $4,730,250 over the last 90 days. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Osaic Holdings Inc. increased its position in Amicus Therapeutics by 450.1% in the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 3,358 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Amicus Therapeutics by 472.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 3,677 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in Amicus Therapeutics by 2,651.5% during the fourth quarter. Farther Finance Advisors LLC now owns 1,871 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,803 shares during the last quarter. GAMMA Investing LLC boosted its stake in Amicus Therapeutics by 167.1% during the 4th quarter. GAMMA Investing LLC now owns 1,987 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,243 shares during the last quarter. Finally, Strs Ohio bought a new position in shares of Amicus Therapeutics during the first quarter worth $30,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.